TD Cowen Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Biogen (NASDAQ:BIIB) had its price target boosted by TD Cowen from $215.00 to $225.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s price objective would indicate a potential upside of 9.49% from the company’s current price.

BIIB has been the subject of several other research reports. HSBC reissued a “reduce” rating and issued a $157.00 target price on shares of Biogen in a research note on Monday, July 6th. Rothschild & Co Redburn boosted their price objective on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Truist Financial upgraded shares of Biogen from a “hold” rating to a “buy” rating and raised their target price for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. Finally, Bank of America lowered their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $222.54.

Biogen Stock Down 1.8%

Shares of Biogen stock traded down $3.72 during trading on Thursday, hitting $205.51. 268,125 shares of the stock were exchanged, compared to its average volume of 1,289,814. The firm’s 50-day moving average price is $200.68 and its 200 day moving average price is $190.37. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen has a 12-month low of $124.56 and a 12-month high of $219.72. The stock has a market cap of $30.34 billion, a price-to-earnings ratio of 22.03 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. During the same period last year, the firm posted $5.47 EPS. Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts forecast that Biogen will post 11.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently modified their holdings of the stock. Insight Wealth Strategies LLC raised its stake in Biogen by 16.9% during the second quarter. Insight Wealth Strategies LLC now owns 34,320 shares of the biotechnology company’s stock worth $7,198,000 after purchasing an additional 4,974 shares during the period. Tema ETFs LLC grew its holdings in shares of Biogen by 5.5% during the 2nd quarter. Tema ETFs LLC now owns 2,772 shares of the biotechnology company’s stock worth $599,000 after purchasing an additional 145 shares during the period. Generali Investments Management Co LLC grew its holdings in Biogen by 4.6% during the 2nd quarter. Generali Investments Management Co LLC now owns 7,437 shares of the biotechnology company’s stock worth $1,607,000 after acquiring an additional 325 shares in the last quarter. Handelsbanken Fonder AB grew its position in Biogen by 12.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 93,236 shares of the biotechnology company’s stock valued at $20,145,000 after buying an additional 10,510 shares in the last quarter. Finally, Charles Schwab Trust Co acquired a new position in shares of Biogen in the 2nd quarter valued at $670,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations, helped by a 24% increase in the Growth Portfolio and contributions from recently acquired Apellis products. Reuters report on Biogen earnings
• Positive Sentiment: Management raised its 2026 revenue outlook to mid-single-digit growth, while newer medicines—including rare-disease treatments and the Alzheimer’s drug Leqembi—are increasingly offsetting declines in legacy multiple sclerosis products. Analysts at Piper Sandler reaffirmed a Buy rating, and Needham maintained its $256 price target. Seeking Alpha report on Biogen outlook
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but retained a Neutral rating, indicating limited conviction despite a potentially higher valuation. Zacks also upgraded the stock from Strong Sell to Hold. Benzinga analyst update
• Negative Sentiment: GAAP net income plunged to $97.5 million from $634.8 million a year earlier, and diluted EPS fell to $0.66 from $4.33. The decline reflects acquisition-related and other costs, raising concerns that underlying profitability may be peaking even as revenue grows. Yahoo Finance analysis of Biogen profitability
• Negative Sentiment: Biogen’s 2026 adjusted EPS guidance of $12 to $13 is below the roughly $13.45 analyst consensus, and reports characterized the update as a reduction to the full-year profit outlook. Legacy MS sales remain under pressure, while Leqembi revenue narrowly missed expectations. Wall Street Journal report on Biogen guidance

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.